AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30784726
Drug: Sham LFMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham LFMS treatment
Trial: 23907736
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy during dental restorations
Trial: 20130470
Drug: Mifepristone 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 75 mg
Trial: 20130470
Drug: Mifepristone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 150 mg
Trial: 20130470
Drug: Mifepristone 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 225 mg
Trial: 17335685
Drug: Thalidomide as
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide as maintenance therapy after double ASCT
Trial: 17335685
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of conventional chemotherapy with novel agents (thalidomide or bortezomib)
Trial: 10825326
Drug: Ephedrine 30
RxNorm normalized name: ephedrine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 30 mg IV
Trial: 10825326
Drug: Ephedrine 10
RxNorm normalized name: pseudoephedrine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 10 mg IV
Trial: 10825326
Drug: Ephedrine 20
RxNorm normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 20 mg IV
Trial: 1430132
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 treatment for 12 hours
Trial: 1430132
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 treatment for 24 hours
Trial: 6494068
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (six different potencies), applied once daily without occlusion
Trial: 6494068
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (six different potencies)
Trial: 2883906
Drug: Metoprolol 25
RxNorm normalized name: metoprolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 25 mg
Trial: 2883906
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no beta-adrenoreceptor antagonist)
Trial: 23311602
Drug: MEAW technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEAW technique with modified Class III elastics from maxillary mini-implants
Trial: 21638181
Drug: Diaphragmatic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragmatic injection of bupivacaine
Trial: 21638181
Drug: Topical wash
RxNorm normalized name: BP 5% Topical Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical wash with bupivacaine
Trial: 21638181
Drug: Control (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sham injection and sham wash)
Trial: 11193132
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate aerosol (1.25 mg)
Trial: 11193132
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate tablet (5 mg)
Trial: 9196354
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (half the dose)
Trial: 9196354
Drug: Budesonide (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (high doses)
Trial: 1350400
Drug: Superficial radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Superficial radiotherapy (SRT) - three fractionated doses of 150 cGy (90 kV, 5 mA, 1.00 mm aluminium filter)
Trial: 30133478
Drug: NASVAC (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASVAC (therapeutic vaccine containing HBsAg and HBcAg, 100 μg each, administered in 2 cycles of 5 doses)
Trial: 30133478
Drug: Peg‐IFN (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN (48 subcutaneous injections of Peg‐IFN alfa 2b, 180 μg per dose, every week for 48 weeks)
Trial: 26728480
Drug: PPV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV plus oral low‐dose CPA (50 mg/day)
Trial: 16649872
Drug: High-dose nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nicotine patch (35 mg)
Trial: 16288408
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and ribavirin combination treatment
Trial: 1970032
Drug: Oestrogen-progesterone (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen-progesterone (0.05 mg ethinyloestradiol plus 1 mg norethisterone daily for 6 months)
Trial: 21610207
Drug: GSK1521498 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1521498 (oral solution and capsule formulations)
Trial: 21610207
Drug: GSK1521498 (10-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1521498 (10-150 mg single doses)
Trial: 15192648
Drug: Trientine hydrochloride
RxNorm normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Trientine hydrochloride (250 mg daily before a meal)
Trial: 15192648
Drug: Trientine hydrochloride
RxNorm normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Trientine hydrochloride (750 mg daily, divided into 3 doses)
Trial: 11756065
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg/d for 14 days)
Trial: 29446830
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester (Kme) supplement (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.45 ml kg-1 body weight)
Trial: 2126745
Drug: Morphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administration in the TPN group
Trial: 2126745
Drug: Morphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administration in the non-TPN group
Trial: 6794167
Drug: No radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No radiation therapy (control group)
Trial: 28124569
Drug: Double percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double percutaneous aspiration injection (DPAI)
Trial: 15179967
Drug: Acamprosate, 1332-1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate, 1332-1998 mg/day
Trial: 15179967
Drug: No anti-relapse
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-relapse medication (control group)
Trial: 8527687
Drug: Experimental controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental controlled release tablet containing pseudoephedrine
Trial: 8527687
Drug: Marketed controlled
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed controlled release pseudoephedrine capsule
Trial: 8527687
Drug: Experimental controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental controlled release tablet containing pseudoephedrine with guaifenesin
Trial: 697082
Drug: Bupivacaine epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine epidural anesthesia (168 +/- 7 mg)
Trial: 17285269
Drug: Propolis (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis (500 mg daily)
Trial: 15121650
Drug: Enhanced counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced counseling and support treatment
Trial: 11704076
Drug: Extraocular light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraocular light therapy (15 patients, 4 M, 11 F)
Trial: 9382120
Drug: Pneumococcal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal and influenza vaccines (PI group)
Trial: 9382120
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine alone (I group)
Trial: 2554722
Drug: HF (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF (high fiber diet with 55 g fiber/day)
Trial: 2554722
Drug: HFS (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFS (high fiber diet with 55 g fiber/day and 15 g sucrose three times daily)
Trial: 2554722
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual diet with about 30 g fiber/day)
Trial: 240014
Drug: Early continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early continuous negative pressure (CNP) treatment before PaO2 < 50 mm Hg on 70% oxygen
Trial: 240014
Drug: Early continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early continuous negative pressure (CNP) treatment
Trial: 240014
Drug: Delayed continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed continuous negative pressure (CNP) treatment
Trial: 16198519
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA, n=38)
Trial: 16198519
Drug: 17beta‐estradiol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA, n=44)
Trial: 16198519
Drug: 17beta‐estradiol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (low E2/NETA, n=50)
Trial: 8214698
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion supplemented with an epidural block with bupivacaine (Group B)
Trial: 8214698
Drug: Alfentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil infusion intravenously (Group A)
Trial: 9378150
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and cyclophosphamide plus doxorubicin (40 mg/m2)
Trial: 9378150
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and cyclophosphamide plus doxorubicin (50 mg/m2)
Trial: 3877279
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 3 mg/kg/h
Trial: 3877279
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 6 mg/kg/h
Trial: 3877279
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 9 mg/kg/h
Trial: 3877279
Drug: All infusion
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All infusion rates (3, 6, 9 mg/kg/h)
Trial: 29654415
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day)
Trial: 31785169
Drug: Daylight photodynamic
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight photodynamic therapy (DPDT)
Trial: 26843523
Drug: Artificial white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial white light photodynamic therapy (AWLPDT)
Trial: 24709267
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation during the intensive phase of TB treatment
Trial: 12437253
Drug: G-100 (<=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-100 (<= 100 mL/d, n = 44)
Trial: 12437253
Drug: G-150 (<=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-150 (<= 150 mL/d, n = 58)
Trial: 12437253
Drug: G-200 (<=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-200 (<= 200 mL/d, n = 37)
Trial: 12437253
Drug: G-val (prospective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-val (prospective validation group, n = 91)
Trial: 10344212
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of finasteride plus terazosin (C)
Trial: 7531900
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg/d) for 12 months
Trial: 1682247
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg/kg body weight)
Trial: 1682247
Drug: Pancuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.1 mg/kg body weight)
Trial: 7159500
Drug: Guar (15.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar (15.6 g/day) + Bezafibrate (600 mg/day)
Trial: 7159500
Drug: Bezafibrate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (600 mg/day) alone
Trial: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 2000 mg/day plus NPLD 60 mg/m2 + cyclophosphamide 600 mg/m2 × 8 cycles Q21 days (arm A)
Trial: 30536182
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (NPLD/C) (arm B)
Trial: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) in patients with HOMA index < 2.5
Trial: 30536182
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone in patients with HOMA index ≥ 2.5
Trial: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) plus chemotherapy (arm A)
Trial: 30536182
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (arm B)
Trial: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) induced diarrhea (G2)
Trial: 27907817
Drug: Featback with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Featback with low‐intensity (weekly) therapist support
Trial: 24848974
Drug: 12 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g/d Soluble maize fibre (SCF)
Trial: 24848974
Drug: 0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/d Soluble maize fibre (Control treatment)
Trial: 18394931
Drug: Gliclazide treatment
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide treatment in Type 2 diabetic patients
Trial: 18394931
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (no gliclazide treatment)
Trial: 15817859
Drug: Selenium as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium as selenomethionine and selenite (highest doses)
Trial: 10597397
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid preceded by pantoprazole, 40 mg (P-PCM)
Trial: 10597397
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid followed by pantoprazole, 40 mg (PCM-P)
Trial: 7489182
Drug: Lexipafant 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lexipafant 60 mg intravenously for 3 days
Trial: 2201157
Drug: alpha 2‐interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha 2‐interferon administered until day 7 of jaundice
Trial: 2201157
Drug: common therapy
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: common therapy (control group)
Trial: 2201157
Drug: alpha 2‐interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha 2‐interferon administered after day 6 of jaundice
Trial: 27936526
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% diclofenac + 3% menthol gel (administered via tube or roll-on device, 4 g applied 4 times daily)
Trial: 27936526
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% diclofenac sodium gel (Voltaren Gel, 4 g applied 4 times daily)
Trial: 27936526
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac sodium tablets (50 mg, 3 times daily)
Trial: 27936526
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% diclofenac + 3% menthol gel
Trial: 27936526
Drug: Voltaren Gel
RxNorm normalized name: Diclofenac Sodium 1% Topical application Gel/Jelly [VOLTAREN GEL]
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Voltaren Gel
Trial: 10838532
Drug: Initial surgical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial surgical resection vs resection after initial chemotherapy
Trial: 8471405
Drug: Losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (25 to 200 mg)
Trial: 8471405
Drug: Losartan (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (multiple dosing for 7 days)
Trial: 3861605
Drug: Enoxacin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin treatment
Trial: 31880758
Drug: LPS Adsorber
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS Adsorber therapy
Trial: 31880758
Drug: Sham Adsorber
RxNorm normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Adsorber therapy
Trial: 18219452
Drug: Trigonella foenum‐graecum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigonella foenum‐graecum L. total saponins (TFGs)
Trial: 10924776
Drug: Spironolactone (MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (MR antagonist), treated for 8 days
Trial: 8651091
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus urokinase (250 U heparin plus 5,000 U urokinase per minute)
Trial: 8651091
Drug: Heparin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (250 U heparin per minute)
Trial: 8651091
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus urokinase
Trial: 1848421
Drug: Vindesine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (3 mg/m2, day 1, 8, 15) plus three cisplatins (35 mg/m2, day 1, 8, 15)
Trial: 1848421
Drug: Vindesine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (3 mg/m2, day 1, 8, 15) plus one cisplatin (80 mg/m2, day 1)
Trial: 20211949
Drug: Drainage, irrigation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drainage, irrigation, and fibrinolytic therapy (DRIFT)
Trial: 20211949
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (tapping off cerebrospinal fluid)
Trial: 12359681
Drug: Quality improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality improvement programs for depression (training experts and nurse specialists, access to nurse specialists for medication follow-up, access to psychotherapists)
Trial: 7725384
Drug: Vicks inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicks inhaler (double dosage)
Trial: 7725384
Drug: Vicks inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicks inhaler (recommended dosage)
Trial: 7032554
Drug: Verapamil, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 120 mg three times a day
Trial: 7032554
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg three times a day
Trial: 25988317
Drug: Memantine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (5 mg/day)
Trial: 17805214
Drug: Aripiprazole 9.4+/‐4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 9.4+/‐4.2 mg/day
Trial: 15542042
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day and 120 mg/day (pooled)
Trial: 3888730
Drug: Limbitrol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limbitrol (25 mg amitriptyline and 10 mg chlordiazepoxide)
Trial: 30679302
Drug: Exenatide plus
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide plus basal insulin
Trial: 27617661
Drug: Olaparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (400 mg twice a day)